Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an announcement.
Shanghai Henlius Biotech, Inc. has entered into a license agreement with Alvogen Korea to commercialize its serplulimab injection, HANSIZHUANG, in South Korea. This agreement grants Alvogen Korea exclusive rights to market the drug for various cancers, potentially enhancing Henlius’s market presence in Asia and providing significant financial milestones and royalties.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development and commercialization of biologic drugs. The company specializes in creating therapies for cancer treatment, with a market focus on innovative biologics for oncology.
YTD Price Performance: 64.35%
Average Trading Volume: 1,626,880
Technical Sentiment Signal: Sell
Current Market Cap: HK$21.17B
Learn more about 2696 stock on TipRanks’ Stock Analysis page.